Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation

Keyphrases

• Small Molecules 100%
• Targeted Cancer Therapy 100%
• Caspase-3 100%
• Overcoming Resistance 100%
• Acquired Resistance 66%
• Fusion Kinase 66%
• MEK Kinase 66%
• Cancer Cells 33%
• In Cancer 33%
• Strategies to Overcome 33%
• Kinase Inhibition 33%
• Specific Inhibitor 33%
• Long-term Efficacy 33%
• Melanoma 33%
• Pathway Inhibitors 33%
• Therapeutic Strategies 33%
• Leukemia 33%
• Lung Cancer 33%
• Oncogenesis 33%
• Drug-induced 33%
• BCR-ABL 33%
• Driver mutations 33%
• PAC1 33%
• Multikinase Inhibitor 33%
• Kinase Inhibitor 33%
• MEK1 33%
• Rapid Onset 33%
• MEK Inhibitor (MEKi) 33%
• EML4-ALK 33%
• Mutant BRAF 33%
• Advanced Cancer 33%
• Combination Effect 33%
• BRAF Fusion 33%
• Mutant EGFR 33%
• EGFR Fusion 33%
• Tumor Histology 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Phosphotransferase 100%
• Procaspase 3 100%
• Phosphotransferase Inhibitor 100%
• Malignant Neoplasm 50%
• Neoplasm 50%
• Carcinogenesis 50%
• Melanoma 50%
• Leukemia 50%
• Caspase 3 50%
• Lung Cancer 50%
• Epidermal Growth Factor Receptor 50%
• Mitogen Activated Protein Kinase Kinase Inhibitor 50%
• Advanced Cancer 50%